<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated the clinical outcome of 92 patients younger than 60 years who were treated between January 1987 and May 2003 </plain></SENT>
<SENT sid="1" pm="."><plain>Low, Int-1, Int-2 and High risk groups categorized by IPSS consisted of 7, 34, 24 and 27 patients, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>There was no significant difference in the overall survival between 30 patients who received allogeneic stem cell transplantation and 62 patients who did not </plain></SENT>
<SENT sid="3" pm="."><plain>Allogeneic stem cell transplantation provided significantly better outcomes in the Int-2 and the High risk groups </plain></SENT>
<SENT sid="4" pm="."><plain>Risk factors for overall survival were age and disease status at transplantation </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD did not influence the relapse free survival rate </plain></SENT>
<SENT sid="6" pm="."><plain>Allogeneic stem cell transplantation is a curative therapy for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>It is necessary to reduce transplantation related <z:hpo ids='HP_0011420'>death</z:hpo> and to perform stem cell transplantation as soon as possible for patients with Int-2 or High risk of IPSS </plain></SENT>
</text></document>